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Abstract 
A growing number of studies show strong associations between stress and altered 
immune function.  In vivo studies of chronic and acute stress have demonstrated that 
cognitive stressors are strongly correlated with high levels of catecholamines (CT) and 
corticosteroids (CS).  Although both CS and CT individually can inhibit the production of 
T-helper 1 (TH1, type-1 like) cytokines and simultaneously promote the production of T-
helper 2 (TH2, type-2 like) cytokines in antigen-specific and mitogen stimulated human 
leukocyte cultures in vitro, little attention has been focused on the effects of combination 
CT and CS in immune responses that may be more physiologically relevant.  We 
therefore investigated the combined effects of in vitro CT and CS upon the type-1/type-2 
cytokine balance of human peripheral blood mononuclear cells (PBMC) as a model to 
study the immunomodulatory effects of superimposed acute and chronic stress.  Results 
demonstrated a significant decrease in type-1 cytokine production (IFN-γ) and a 
significant increase in type-2 cytokine production (IL-4, IL-10) in our CS+CT incubated 
cultures when compared to either CT or CS agents alone.  Furthermore, variable 
enhancement of type-1/type-2 immune deviation occurred depending upon when the CT 
was added.  The data suggest that CS can increase the sensitivity of PBMC to the 
immunomodulatory effects of CT and establishes an in vitro model to study the combined 
effects of in vivo type-1/type-2 cytokine alterations observed in acute and chronic stress. 
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Introduction 
A growing body of literature recognizes the dynamic interactions between components of 
the nervous, endocrine, and immune systems as a cohesive unit responsible for protection 
of the host (1-4).  In this model, products of the hypothalamic-pituitary-adrenal axis (HPA) 
and the sympathetic nervous system (SNS) shift immunity from an intracellular 
pathogen-specific (TH1, type-1 like) immune response to an extracellular pathogen-
specific (TH2, type-2 like) response during times of high psychological stress (1, 4).  
Although this model of immune deviation is an adaptive mechanism that protects the host 
from the sequelae of systemic inflammation (3), maladaptive responses to stress-induced 
immune deviation may exacerbate and/or contribute to the pathogenesis of immune-based 
clinical disorders (5). 
 
In vivo studies of chronic and acute stress situations such as those modeled by the Trier 
Social Stress Test (TSST) and seen in the medical student exam stress model (MSESM) 
have demonstrated that cognitive stressors such as public speaking and medical student 
exams are strongly correlated with high levels of CT and/or CS (6, 7).  In addition, stressful 
events (particularly chronic) have been associated with adverse clinical effects such as 
viral reactivation and exacerbation of inflammatory disorders (7, 8).  It seems reasonable to 
speculate that acutely stressful events might have an even more adverse clinical effect in 
individuals already chronically stressed, but this has not been well documented. 
 
It has long been suggested that these effects can be partially explained by alterations of 
the cytokine network responsible for an optimally protective adaptive immune response 
(7).  Studies by our group and others have shown that products of the HPA and SNS, 
namely CS and the CT epinephrine (EPI) and norepinephrine (NE) can alter the balanced 
expression of cytokines from TH1 in favor of TH2 in vitro (9-12).  Specifically, 
dexamethasone (DEX, a corticosteroid analog for cortisol used for its stable in vitro 
properties), EPI, and/or NE added as single agents at the initiation of cultures can alter 
the cytokine network responsible for the adaptive immune response by inhibiting the in 
vitro production of type-1 cytokines (IFN-γ, IL-12) while favoring the production of 
type-2 cytokines (IL-4, IL-10, IL-13) (10-12).   
 
While studies have largely investigated the individual effects of in vitro CS or CT in 
immune deviation, little attention has been focused upon the in vitro effects of 
combination CT and CS in immune responses that may be more physiologically relevant 
to the TRIER and medical student exam stress models.  For example, CS can influence 
the long-term responses of various tissues  to CT by increasing β-adrenergic receptor 
surface (β2-AR) expression and intracellular cAMP activity in human smooth muscle 
cells (13) and epithelial cells (14, 15) lining the respiratory tract.  More recent data suggest 
that β2-AR expression on lymphocytes and APC may respond similarly to the long-term 
modulation of CS in murine and equine models (16-18).  In vitro exposure to CS can 
increase β2-AR expression and cAMP activity in murine lymphocytes in vitro (16) and 
murine and equine lymphocytes in vivo (17, 18).  Furthermore, the combination of CT and 
CS decreased the pro-inflammatory cytokines IL-8, IL-6, and TNF-α in vitro from 
synovial tissue isolated in patients with rheumatoid arthritis (19).  Although documented, 
the combined effects of endogenous CS and CT on the type-1/type-2 cytokine network in 
human leukocytes are limited in the literature and have not been well studied. 
 
We therefore studied the combined physiological stress equivalents of endogenous CS 
and CT on antigen-specific stimulated human PBMC as an in vitro model of the 
immunomodulatory effects of superimposed chronic and acute stressors (i.e., 
neuroendocrine stress hormones).  Our studies demonstrate that the combined effects of 
in-vitro CS and CT significantly decreases the production of type-1 cytokines and 
simultaneously increases the expression of type-2 cytokines in our antigen-specific 
stimulated PBMC cultures when compared to either CS or CT agents alone.  These 
effects further shifted the balanced production of type-1/type-2 cytokines in favor of a 
type-2 response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
Reagents: EPI, NE, phorbol myristate acetate (PMA), ionomycin, and DEX were 
purchased from Sigma Chemicals (St. Louis, MO).  Recombinant rhIL-2 was a gift from 
Dr. Jeffrey Rossio at the NIH-Frederick Cancer Research Center (Bethesda, MD).  
Tetanus toxoid (TT) was purchased from Massachusetts Biologic Laboratories (Boston, 
MA).  ELISA kits are from Pharmingen (San Diego, CA).   
Subjects:  Fourteen healthy study subjects (evenly distributed between men and women) 
aged 18-50 were recruited for participation in the study (blood draws).  Subjects were 
excluded for any past medical history of smoking, psychiatric illnesses, cardiovascular 
diseases, or recent medical use of CS, CT, and adrenergic antagonists.  Blood samples 
were drawn in the morning between 0800 and 1200 hours to control for diurnal variation 
in immune responses.  The Committee for the Protection of Human Subjects (CPHS) at 
the University of Texas Medical School at Houston approved protocols for the study.  
Informed consent was obtained from each subject prior to enrollment.   
Isolation of PBMC:  Venous blood was collected in heparinized Vacutainer tubes 
(Becton Dickinson, San Diego, CA) and PBMC were isolated via ficoll-hypaque density 
gradient centrifugation at 3000g for 20 minutes.  Cells were washed twice with 
Ca2+/Mg2+ free HBSS (Sigma), and resuspended in RPMI 1640 supplemented with 
90U/ml penicillin, 90 μg/ml streptomycin, 2mMol/L L-Glutamine (all from Sigma), and 
10% human AB serum (Atlanta Biologicals).   
PBMC Cultures: For incubation experiments, DEX at concentrations of 1x10-8 M 
(mimicking the stress-physiologic plasma levels (11) of endogenous glucocorticoids) was 
added on the first day of stimulation followed by the addition of EPI or NE at the stress 
physiologic concentrations (1x10-8 M, 1x10-7 M, respectively) on fifth and tenth days of 
stimulation.  PBMC Cultures at 1x106 cells/ml were stimulated with 0.5 μg/ml TT and 10 
IU/ml rhIL-2 for 5 days at 37oC and 5% carbon dioxide for all experiments as previously 
described (11, 12).  On day 5, 0.5 ml of supernatant was removed and replaced with 20 
IU/ml rhIL-2 for cellular expansion and 0.5 ml fresh media containing 10% human AB 
serum.  On day 10, 0.5 ml of supernatant was removed and replaced with 0.5 ml media 
containing 10 μg/ml phytohemagluttinin (PHA) and 1 ng/ml phorbol myrisitate acetate 
(PMA) and incubated for 24 hours as previously described (11, 12).  Briefly, a clonal 
population of antigen specific T-lymphocytes predominates by the end of the 11 day 
culture period.  These clonal cells are stimulated with PHA and PMA on the 10th day of 
culture for 24 hours to amplify the production of cytokines from phenotypically 
committed cells that otherwise produce cytokines at levels too low for detection by 
ELISA.  The use of mixed-cell cultures such as PBMC is closer to physiological 
conditions than cultures using isolated CD4+ naïve T-cells for our set of experiments.  
For cultures coincubated with both CS and CT (simulating acute stress episodes 
superimposed upon chronic stress), EPI was added for convenience on the 5th and 10th 
days at the same time the media was scheduled for change as previously described (11, 12).   
Supernatants were harvested on day 11 and stored at -70oC.   
Cytokine analysis: Levels of type-1 and type-2 cytokines in culture supernatants were 
determined by enzyme linked immunosorbent assays (ELISA) using paired antibodies 
specific for IFN-γ, IL-10, and IL-4 (Pharmingen).  Developed ELISA plates were read on 
an Emax plate reader (Molecular Devices) at 450nm.  Sample concentrations were 
determined based on calculated standard curves using SOFTmax (Molecular Devices).  
The lower limit of detection of the IFN-γ, IL-10, and IL-4 kits was 4 pg/ml. 
Statistical methods: Cytokine data (with the exception of Type-1/Type-2 ratio data) 
were transformed into a logarithmic scale (Log10) to normalize the results, thus bringing 
the data closer to a Gaussian distribution.  Data are presented in graph form as mean ± 
standard deviation (SD).  Type-1/Type-2 cytokine ratios were calculated from 
untransformed cytokine values for each individual and culture condition before 
summarized in bar graph format.  The data are presented as mean ± SD.  Comparisons 
between 3 or more groups utilized the repeated measures one-way analysis of variance 
(ANOVA) with post test analysis for group differences by Tukey’s Multiple 
Comparisons Test.  Statistical analyses were calculated with Prism (Version 4.0 
Graphpad Software, San Diego, CA). 
 
Results 
 
Decreased Production of Type-1 Cytokines by Combined Physiological Stress Levels 
of Corticosteroids and Catecholamines  
To determine the combined effects of adrenergic agents and CS, we used physiological 
stress concentrations of EPI (12) and DEX (mimicking the stress-physiologic plasma 
levels of endogenous glucocorticoids) (11) together or as single agents.  In these sets of 
experiments IFN-γ levels were determined in culture supernatants from TT stimulated 
cultures treated with combination DEX at 10-8 M and EPI at 10-8 M.  Coincubation 
cultures with DEX and EPI were added either on day one of stimulation (DEX+EPI1) or 
DEX on the 1st day followed by EPI added on 5th and 10th days of antigenic stimulation 
(DEX+EPI5,10).  In addition, DEX, EPI1 (added as a single agent on the first day of 
stimulation) and EPI5, 10 (EPI added as a single agent on the 5th and 10th days of 
stimulation) groups were added as supplementary controls.  The means from the 
treatment groups differed significantly by repeated measures ANOVA (p<0.0001).  
Tukey’s post-test analysis (TPTA) revealed significant inhibition of IFN-γ production 
from baseline control in the DEX, EPI1, DEX+EPI1, DEX+EPI5,10 groups.   In addition, 
TPTA demonstrated significantly more inhibition of IFN-γ production from both the 
DEX and DEX+EPI1 groups.  The mean of the DEX+EPI1 treated group did not differ 
significantly from the DEX treated group, suggesting that the inhibition of IFN-γ in the 
DEX+EPI1 group was due to DEX and not to the additive effect of EPI in long-term 
antigen-specific stimulated cultures (Figure 1).   
 
Increased Production of Type-2 Cytokines by Combined Stress Levels of 
Corticosteroids and Catecholamines 
Production of IL-10 and IL-4 production was determined from the same culture 
supernatants described above.  The means for both IL-4 and IL-10 among the treatment 
groups differed significantly by repeated measures ANOVA (p<0.0001).  TPTA revealed 
a significant increase of IL-10 production in the DEX, EPI1, DEX+EPI1, and 
DEX+EPI5,10 groups from baseline control (Figure 2).  In addition, TPTA revealed a 
significant increase in IL-4 production in the EPI1 and DEX+EPI5,10 groups but not the 
DEX, EPI5,10, or DEX+EPI1 groups when compared to control (Figure 3).  Furthermore, 
TPTA revealed that the DEX+EPI5,10 group significantly increased the production of IL-4 
and IL-10 over the DEX, DEX+EPI1, and EPI1 groups (Figures 2, 3). 
 
A balanced production of cytokines is needed for an adaptive immune response that is 
appropriate for the inciting antigen (20).  To further investigate the impact of CS and CT 
on this balance, type-1/type-2 cytokine ratios were calculated based upon cytokine 
expression levels for all treatment groups demonstrated in Figures 1-3.  The group means 
in the IFN-γ/IL-10 graph (Figure 4) and IFN-γ/IL-4 (Figure 5) differed significantly by 
repeated measures ANOVA (p<0.0001).  The IFN-γ/IL10 ratios were significantly 
decreased in the DEX, EPI1, DEX+EPI1, and DEX+EPI5,10 groups when compared to 
baseline control from TPTA (Figure 4).  Similarly, the IFN-γ/IL-4 ratios were 
significantly decreased in the DEX, EPI1, DEX+EPI1, and DEX+EPI5,10 groups from 
baseline control (Figure 5) by TPSA.  The type-1/type-2 ratio in the DEX+EPI5,10 group 
was significantly less than the DEX, EPI1, and DEX+EPI1 by TPTA In both the type-
1/type-2 graphs (Figures 4 and 5), demonstrating that the additive effects of EPI added 
several days later to long-term antigen-specific cultures significantly decreased the 
balanced production of cytokines further in favor of type-2 cytokines.     
 
Propanolol Blocks the Type-2 Cytokine Shift from the Additive Effects of β2-
Agonists 
We wished to investigate if the cooperative effects of CS and CT were mediated in part 
by the β2-adrenergic receptor (β2-AR).  Previously, PRO, a non-selective β-adrenergic 
receptor antagonist, has been shown to mitigate the in vitro effects of catecholamines in 
antigen-specific PBMC cultures (X).  The mean production of IFN-γ, IL-10, and IL-4 in 
the DEX+EPI5,10+PRO  group did not significantly differ from the DEX group (Figures 1 
- 3) by TPTA.  However, the mean production of IFN-γ in the DEX+EPI5,10 group was 
significantly less than the DEX+EPI5,10+PRO group by TPTA.  In addition, the mean 
production of type-2 cytokines (IL-10 and IL-4) were significantly higher in the 
DEX+EPI5,10 group than the DEX+EPI5,10+PRO group by TPTA suggesting that the 
observed differences were mediated by β-agonists (Figures 1 - 3).  In addition, the type-
1/type-2 ratios between the DEX+EPI5,10+PRO and the DEX groups (Figure 4, 5) did not 
significantly differ by TPTA  suggesting that the significant differences between the 
DEX+EPI5,10 and DEX groups were mediated by β-agonists (Figures 4, 5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Recent studies have shown that CT amplify the anti-inflammatory effects of CS in 
fibroblasts and smooth muscle cells (21-24), thus attenuating the effects of CT-induced 
tachyphylaxis of the β2-AR (β2-AR desensitization) in human respiratory smooth muscle 
cells (22, 25).  In addition, the combination of CT and CS has a cooperative anti-
inflammatory effect on synovial tissue by inhibiting type-1 cytokines in vitro and in vivo 
(19).  Furthermore, the combined effects of pharmacologically available adrenergic 
agonists with CS suppress T-cell proliferation and type-1 cytokine production in short-
term mitogen-stimulated human PBMC cultures in vitro, although variable effects were 
observed with type-2 cytokines (26).  However, these observations do not address 
physiologic parameters such as the use of stress doses of endogenous CT with CS on 
antigen-specific immune responses that would model in vivo stress-induced immune 
dysfunction. 
 
The goal of the study was to develop an in vitro antigen-specific model to examine the 
immune effects of endogenous CT stress hormones that appear acutely in the context of 
chronic stress CS hormones.  These experiments demonstrated that the combination of 
CS and CT significantly decreased the production of IFN-γ and simultaneously increased 
the production of IL-10 and IL-4 when compared to either agent alone (Figures 1-5).  
Furthermore, the balanced production of type-1/type-2 cytokines significantly shifted 
towards a type-2 cytokine profile in the DEX+EPI5,10 group over the DEX+EPI1, DEX, 
and EPI1 groups (figures 4, 5).  The EPI-mediated cytokine alterations were blocked by 
PRO indicating that the cooperative effects were mediated through the β2-AR.  Our 
results are novel in that both type-2 cytokines in our study (IL-4 and IL-10) were 
significantly increased and IFN-γ was significantly decreased using long-term antigen-
specific stimulated human PBMC cultures.  In addition, these results were obtained using 
physiologic stress concentrations of endogenous CT (EPI, NE) in contrast to therapeutic 
doses of pharmacologically available long-acting β-agonists in short-term mitogen-
stimulated cultures.   
 
Of note, we observed variations in cytokine expression levels from different study 
subjects.  For example, the DEX+EPI5,10 group had significantly lower type-1 cytokine 
production and increased type-2 cytokines, although some individuals were more 
sensitive than others to the cooperative effects of CS and CT.  These within group 
differences may be at least partially explained by subject heterogeneity such as functional 
polymorphisms of the β2-AR (27-29), glucocorticoid receptor (30, 31), and cytokine receptors 
(32, 33).  In addition to polymorphisms, different isoforms of the GCR due to transcript 
alternative splicing and alternative translation initiation (34-36) may also contribute to 
variation of cytokine expression and potentially immune deviation of the type-1/type-2 
cytokine balance.  These possibilities await future investigation. 
 
Kinetic differences were observed between our DEX+EPI1 and DEX+EPI5,10 cultures 
(Figures 1-5).  In particular, these two treatment groups demonstrated that the cooperative 
effects of combination CS and endogenous CT in antigen-specific cultures appear at later 
time points (DEX+EPI5,10 cultures) rather than earlier exposure to adrenergic agents 
(DEX+EPI1 cultures) in our antigen-specific cultures.  Combined with the adrenergic 
antagonist data with PRO, the data suggest that the mechanism responsible for these 
observations is time-dependent and may therefore require modification or de novo 
synthesis of the AR or CS signaling apparatus after antigenic-stimulation.  Possible 
mechanisms may include increased nuclear translocation of the GCRC (26), increased cell 
surface AR density and function (from de novo synthesis or redistribution of internalized 
receptors between the internal and external cellular compartments), and/or increased 
secondary signaling from the AR. 
 
Although our DEX+EPI1 data differed from those previously reported by Goleva et al (26), 
several differences in the experimental design may explain these discrepancies.  Goleva 
et al used short-term mitogen stimulation (PMA and Ionomycin) vs. long-term antigen-
specific cultures (TT) used in our study.  Mitogen stimulation requires shorter incubation 
periods than antigen-specific stimulation due to bypassing antigen presentation, 
costimulation by the B7 receptor family (i.e., B7.1, B7.2), and differentiation of naïve T-
cells (TH0) into TH1 and TH2 clones.  Moreover, the physical and biological differences 
between endogenous CT and long-acting synthetic β-agonists such as salmeterol include 
elimination half-lives of 2-3 minutes for EPI compared to 5.5 hours (37, 38) for salmeterol 
due in part to the lipophilic nature of salmeterol, reduced ability of salmeterol to induce 
tachyphylaxis of β2-AR (38), alternate routes of metabolism, and the relative instability of 
endogenous CT (EPI and NE) at culture pH and temperature.  In effect, these differences 
may allow for the in vitro manifestations of long-acting β-agonists on PBMC to appear 
more readily in short term cultures than the additive effects of EPI or NE manifested in 
long-term antigen-specific cultures until later time points.   
 
Based upon preliminary experiments, the likely sources of expressed cytokines in our 
long-term antigen-specific cultures were clonal populations of tetanus-specific CD4+ T-
lymphocytes.  Greater than 90% of the viable cells remaining in culture at day 11 were 
CD4+ T-lymphocytes, 5-9% were CD8+ T-lymphocytes, and less than 1% were CD19+ 
B-lymphocytes (data not shown).  CD14+ APC, also a source of IL-10, were not 
detected.  This suggests that immune deviation of the type-1/type-2 paradigm had 
occurred primarily at the level of the T-cell in our in vitro model. 
 
In summary, our study was designed to establish an in vitro human model of stress 
hormone-induced immune changes.  This model demonstrated that the combination of CS 
and CT enhanced immune deviation of the cytokine network towards a type-2 adaptive 
immune response to recall antigen (TT) in vitro.   Future research will explore possible 
mechanisms for the cooperative effects of combination CS and CT on immune function 
such as changes in the function and expression of β2-AR on specific leukocyte 
populations (lymphocytes and APC) as a complementary mechanism to increased nuclear 
translocation of the GCRC.  Additionally, our in vitro model can serve as a guide to 
developing future clinical studies that will investigate specific immune dysfunction after 
acutely stressful situations in patients who are already chronically stressed.  
Understanding these effects should allow development of interventional strategies to 
mitigate or prevent the adverse immunological effects of acute and chronic stress in 
patients with various inflammatory diseases. 
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EPI subsequently added on the 5th and 10th days of culture
PRO = Beta receptor blockade by propranolol
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Figure 1: Detection of IFN-γ production in 11-day Tetanus-Toxoid (TT) stimulated cultures by 
ELISA.  The data represent the effects of physiologic-stress doses of CT added at different 
time points (EPI1, EPI5,10), CS (DEX), and the combination of CT+CS (DEX+EPI1, 
DEX+EPI5,10) in human PBMC from a sample size of 14 healthy adults.  Data are represented 
as mean ± standard deviation.   * = p<0.5, ** = p<0.001, and represented p values calculated by 
Tukey’s Multiple Comparisons test.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
IL-10 Production
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Figure 2: Detection of IL-10 production in 11-day TT (antigen-specific) stimulated cultures by 
ELISA.  The data represent the effects of physiologic-stress doses of CT added at different 
time points (EPI1, EPI5,10), CS (DEX), and the combination of CT+CS (DEX+EPI1, 
DEX+EPI5,10) in human PBMC from a sample size of 14 healthy adults.  Data are represented 
as mean ± standard deviation.   * = p<0.5, ** = p<0.001, and represented p values calculated by 
Tukey’s Multiple Comparisons test.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
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Figure 3: Detection of IL-4 production in 11-day TT (antigen-specific) stimulated cultures by 
ELISA.  The data represent the effects of physiologic-stress doses of CT added at different 
time points (EPI1, EPI5,10), CS (DEX), and the combination of CT+CS (DEX+EPI1, 
DEX+EPI5,10) in human PBMC from a sample size of 14 healthy adults.  Data are represented 
as mean ± standard deviation.   * = p<0.5, ** = p<0.001, and represented p values calculated by 
Tukey’s Multiple Comparisons test.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
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Figure 4: The balanced production of cytokines determines the adaptive immune response.  
Type-1/Type-2 (IFN-γ/IL-10) cytokine ratios were calculated from ELISA data of 11-day TT 
(antigen-specific) stimulated cultures.  The balanced production of cytokines determines the 
adaptive immune response.  Type-1/Type-2 (IFN-γ/IL-10) cytokine ratios were calculated from 
ELISA data of 11-day TT (antigen-specific) stimulated cultures.  The data represent the effects 
of physiologic-stress doses of CT added at different time points (EPI1, EPI5,10), CS (DEX), the 
combination of CT+CS (DEX+EPI1, DEX+EPI5,10), or CT+CS+propranolol (DEX+EPI5,10 
+PRO) in human PBMC from a sample size of 14 healthy adults.  Data are represented as 
mean ± standard deviation.   ** = p<0.001 and represented p values were calculated by 
Tukey’s Multiple Comparisons test.   
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Type-1/Type-2 Ratio
Control EPI 1 EPI 5,10 DEX DEX+EPI 1 DEX+EPI 5,10 DEX+EPI 5,10+PRO
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
32
p<0.05
ns
**
**
**
**
**
ns
p<0.05
p<0.001
IF
N
- γ/
IL
-4
  R
at
io
 
Figure 5: The balanced production of cytokines determines the adaptive immune response.  
Type-1/Type-2 (IFN-γ/IL-4) cytokine ratios were calculated from ELISA data of 11-day TT 
(antigen-specific) stimulated cultures.  The balanced production of cytokines determines the 
adaptive immune response.  Type-1/Type-2 (IFN-γ/IL-10) cytokine ratios were calculated from 
ELISA data of 11-day TT (antigen-specific) stimulated cultures.  The data represent the effects 
of physiologic-stress doses of CT added at different time points (EPI1, EPI5,10), CS (DEX), the 
combination of CT+CS (DEX+EPI1, DEX+EPI5,10), or CT+CS+propranolol (DEX+EPI5,10 
+PRO) in human PBMC from a sample size of 14 healthy adults.  Data are represented as 
mean ± standard deviation.   ** = p<0.001 and represented p values were calculated by 
Tukey’s Multiple Comparisons test.   
